What is the significance of this filing being an amendment (10-Q/A)?

A 10-Q/A filing means that Pfizer is amending its previously filed Quarterly Report (10-Q). This indicates that there was information in the original filing that needed correction, clarification, or addition. Investors should pay close attention to the amended sections to understand the nature of the changes and their potential impact.

What specific financial details can I find in this excerpt?

The provided excerpt is a directory listing and does not contain detailed financial statements or management's discussion and analysis. To understand Pfizer's financial performance for the period ending June 27, 1998, investors would need to access the full text of the 10-Q/A filing, specifically focusing on the sections that were amended.

What should investors look for when reviewing this amended filing?

Investors should look for the specific reasons stated for the amendment, any updated financial figures (revenue, net income, expenses), changes in risk factors, management's commentary on the updated information, and any disclosures regarding legal or regulatory matters that may have been revised. The goal is to understand what new or corrected information has been provided and how it affects the company's financial health and outlook.

Where can I find the full text of the 10-Q/A filing for Pfizer Inc. filed on September 24, 1998?

The full text of the filing can typically be accessed through the SEC's EDGAR database. You would search for Pfizer Inc. (PFE) and the specific filing type (10-Q/A) with the filing date of September 24, 1998, or the period ending June 27, 1998.

PFE 10-Q Quarterly Report Q2 FY1998 — Revenue, Net Income, EPS

Summary

Pfizer Inc.'s 10-Q/A filing for the period ending June 27, 1998, represents an amendment to their quarterly report. While specific financial performance details are not fully detailed in the provided filing excerpt, the amendment suggests that there were adjustments or additional information to be disclosed regarding the company's operations for the second quarter of 1998. Investors should interpret this as an opportunity for a more complete understanding of Pfizer's financial position and performance, and a signal to carefully review the amended sections for any material changes. Given this is an amendment, the primary focus for investors would be to understand what specific information has been updated or clarified. Typically, amendments address previously omitted information, correct errors, or provide updated disclosures. Therefore, a thorough review of the amended sections of the full filing is crucial to grasp the full implications for Pfizer's financial health and future outlook, particularly concerning its product pipeline, sales, and any potential liabilities or strategic shifts that might have been refined.

Key Highlights

1This filing is an amendment (10-Q/A) to Pfizer Inc.'s quarterly report for the period ending June 27, 1998.
2The amendment indicates that previously filed information may have been updated, corrected, or supplemented.
3Investors are advised to carefully examine the specific changes made in the amendment to understand any material impact on Pfizer's financial standing.
4The filing pertains to Pfizer's operations during the second quarter of fiscal year 1998.
5While the provided excerpt lacks detailed financial tables, the amendment itself is a key piece of information for understanding the company's reporting accuracy and completeness.
6The filing underscores the importance of reviewing all amendments to SEC filings for a comprehensive view of a company's financial narrative.

PFIZER INC Quarterly Report (Amendment) for Q2 Ended Jun 28, 1998

Summary

Key Highlights

Frequently Asked Questions